Evidence map›Paper›PMID 38767512›Full record

ArticleHuman gene therapy2024

AAV5 Delivery of CRISPR/Cas9 Mediates Genome Editing in the Lungs of Young Rhesus Monkeys.

Shun-Qing Liang, Andrew W Navia, Michelle Ramseier, Xuntao Zhou, Michele Martinez, Charles Lee, Chen Zhou, Joae Wu, Jun Xie, Qin Su and 7 more

Abstract read
In one paragraph

Article in Human gene therapy, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Review
  2. Review
  3. Review
  4. Article
  5. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors.

Shun-Qing LiangRNA Therapeutics Institute, University of Massachusetts Medical School, Worcester, Massachusetts, USA.
Andrew W NaviaInstitute for Medical Engineering and Science, Department of Chemistry, and Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, Massachusetts, USA.
Michelle RamseierInstitute for Medical Engineering and Science, Department of Chemistry, and Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, Massachusetts, USA.
Xuntao ZhouRNA Therapeutics Institute, University of Massachusetts Medical School, Worcester, Massachusetts, USA.
Michele MartinezDepartments of Pediatrics and Cell Biology and Human Anatomy, School of Medicine, and California National Primate Research Center, University of California, Davis, California, USA.
Charles LeeDepartments of Pediatrics and Cell Biology and Human Anatomy, School of Medicine, and California National Primate Research Center, University of California, Davis, California, USA.
Chen ZhouHorae Gene Therapy Center and Department of Microbiology and Physiological Systems, University of Massachusetts Medical School, Worcester, Massachusetts, USA.
Joae WuDepartment of Pediatrics, University of Massachusetts Medical School, Worcester, Massachusetts, USA.
Jun XieHorae Gene Therapy Center and Department of Microbiology and Physiological Systems, University of Massachusetts Medical School, Worcester, Massachusetts, USA.ORCID 0000-0001-9565-1567
Qin SuHorae Gene Therapy Center and Department of Microbiology and Physiological Systems, University of Massachusetts Medical School, Worcester, Massachusetts, USA.
Dan WangHorae Gene Therapy Center and Department of Microbiology and Physiological Systems, University of Massachusetts Medical School, Worcester, Massachusetts, USA.ORCID 0000-0001-9079-2360
Terence R FlotteHorae Gene Therapy Center and Department of Microbiology and Physiological Systems, University of Massachusetts Medical School, Worcester, Massachusetts, USA.
Daniel G AndersonDepartment of Chemical Engineering, Massachusetts Institute of Technology, Cambridge, Massachusetts, USA.
Alice F TarantalDepartments of Pediatrics and Cell Biology and Human Anatomy, School of Medicine, and California National Primate Research Center, University of California, Davis, California, USA.
Alex K ShalekInstitute for Medical Engineering and Science, Department of Chemistry, and Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, Massachusetts, USA.
Guangping GaoHorae Gene Therapy Center and Department of Microbiology and Physiological Systems, University of Massachusetts Medical School, Worcester, Massachusetts, USA.
Wen XueRNA Therapeutics Institute, University of Massachusetts Medical School, Worcester, Massachusetts, USA.ORCID 0000-0003-4664-6029

Funding

National Institute on Aging (NIA) ColonyP51OD011107 · OD · UNIVERSITY OF CALIFORNIA AT DAVIS · PI Simon J. Atkinson · 2012 to 2026
$191.5M
Vector Immunology CoreP01HL158506 · NHLBI · UNIV OF MASSACHUSETTS MED SCH WORCESTER · PI Dan Wang · 2021 to 2026
$19.5M
SCGE Comparative Studies SupplementU42OD027094 · OD · UNIVERSITY OF CALIFORNIA AT DAVIS · PI HARTIGAN-O'CONNOR, DENNIS J., SEGAL, DAVID J · 2019 to 2023
$14.2M
Viral Vector CoreP01HL131471 · NHLBI · UNIV OF MASSACHUSETTS MED SCH WORCESTER · PI MUELLER, CHRISTIAN · 2016 to 2020
$11.3M
Develop combinatorial non-viral and viral CRISPR delivery for lung diseasesUH3HL147367 · NHLBI · UNIV OF MASSACHUSETTS MED SCH WORCESTER · PI ANDERSON, DANIEL G, GAO, GUANGPING · 2021 to 2022
$2.9M
Develop combinatorial non-viral and viral CRISPR delivery for lung diseasesUG3HL147367 · NHLBI · UNIV OF MASSACHUSETTS MED SCH WORCESTER · PI ANDERSON, DANIEL G, GAO, GUANGPING · 2018 to 2020
$2.7M
In vivo prime editing for precision cancer mouse modelsR01CA275945 · NCI · UNIV OF MASSACHUSETTS MED SCH WORCESTER · PI Wen Xue · 2023 to 2026
$2.5M
CRISPR-based modular therapy for precision medicineDP2HL137167 · NHLBI · UNIV OF MASSACHUSETTS MED SCH WORCESTER · PI XUE, WEN · 2016 to 2016
$2.5M
PET/CT for Nonhuman Primate ImagingS10RR025063 · NCRR · UNIVERSITY OF CALIFORNIA AT DAVIS · PI TARANTAL, ALICE F · 2011 to 2011
$2.1M
miniEXPLORER-II for Total-Body PET Translational ImagingS10OD028713 · OD · UNIVERSITY OF CALIFORNIA AT DAVIS · PI TARANTAL, ALICE F · 2020 to 2020
$1.9M
NCI NIH HHS R01 CA275945NCRR NIH HHS S10 RR025063NHLBI NIH HHS DP2 HL137167NHLBI NIH HHS P01 HL131471NHLBI NIH HHS P01 HL158506NHLBI NIH HHS UG3 HL147367NHLBI NIH HHS UH3 HL147367NIH HHS P51 OD011107NIH HHS S10 OD028713
6 · The paper itself

Abstract

Genome editing has the potential to treat genetic diseases in a variety of tissues, including the lung. We have previously developed and validated a dual adeno-associated virus (AAV) CRISPR platform that supports effective editing in the airways of mice. To validate this delivery vehicle in a large animal model, we have shown that intratracheal instillation of CRISPR/Cas9 in AAV5 can edit a housekeeping gene or a disease-related gene in the lungs of young rhesus monkeys. We observed up to 8% editing of

Indexed as

CRISPR-Cas SystemsDependovirusGene EditingGenetic VectorsLungMacaca mulattaAngiotensin-Converting Enzyme 2AnimalsGenetic TherapyHumansAngiotensin-Converting Enzyme 2AAV5CRISPRlungrhesus monkey

Identifiers

PMID38767512
PMCPMC11511778

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.